Bumper Offer - Urjas oil Just @ Rs. 1
Atorsave Gold 10 Tablet (10) is a commercial drug that is prescribed in the form of Tablet. High Cholesterol are some of its major therapeutic uses. Other than this, Atorsave Gold 10 Tablet (10) has some other therapeutic uses, which have been discussed ahead.
Medical history of the patient along with age and gender determines the dosage of Atorsave Gold 10 Tablet (10). Individual symptoms and route of administration also determines the right dosage. This information has been provided in detail in the dosage section.
The most common side effects of Atorsave Gold 10 Tablet (10) are Headache, Nasopharyngitis, Diarrhoea. Apart from the aforementioned side effects, Atorsave Gold 10 Tablet (10) can also lead to other problems, which have been listed below. Normally, these side effects of Atorsave Gold 10 Tablet (10) are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
It is also important to note that Atorsave Gold 10 Tablet (10) has a Severe effect for pregnant women and Mild effect on lactating mothers. It is important to know if Atorsave Gold 10 Tablet (10) has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Atorsave Gold 10 Tablet (10) related warnings section.
Atorsave Gold 10 Tablet (10) is not recommended if you suffer from certain medical conditions as it can have adverse effects. Liver Disease, Alcoholism are examples of such conditions. The section on Atorsave Gold 10 Tablet (10) contraindications lists all such conditions.
Besides this, Atorsave Gold 10 Tablet (10) may also have severe interaction with some medicines. See below for a complete list.
In addition to the above precautions for Atorsave Gold 10 Tablet (10), it is important to know that it is safe while driving, and is habit-forming.
Atorsave Gold 10 Tablet (10) is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
Based on research, the following side effects have been observed when Atorsave Gold 10 Tablet (10) is used -
Moderate
Mild
Common
Is the use of Atorsave Gold 10 Tablet (10) safe for pregnant women?
Atorsave has many dangerous side effects in pregnant women. If you are pregnant, do not consume Atorsave without medical advice.
Is the use of Atorsave Gold 10 Tablet (10) safe during breastfeeding?
Atorsave has been seen to have minimal side effects on breastfeeding women.
What is the effect of Atorsave Gold 10 Tablet (10) on the Kidneys?
Atorsave may cause harmful effects on kidney. if you feel its having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Atorsave Gold 10 Tablet (10) on the Liver?
Atorsave can have moderate side effects on the liver. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Atorsave Gold 10 Tablet (10) on the Heart?
Atorsave may have mild side effects on the heart. Most people will never see any effect on the heart.
Atorsave Gold 10 Tablet (10) should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Atorsave Gold 10 Tablet (10) unless your doctor advises you to do so -
Is this Atorsave Gold 10 Tablet (10) habit forming or addictive?
No, there is no any evidence that Atorsave Gold 10 Tablet (10) is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Yes, it is safe to do these activities or work after taking Atorsave Gold 10 Tablet (10) as it does not make you drowsy.
Is it safe?
Yes, Atorsave Gold 10 Tablet (10) is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking Atorsave Gold 10 Tablet (10) for mental disorders.
Interaction between Food and Atorsave Gold 10 Tablet (10)
Taking Atorsave Gold 10 Tablet (10) with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Atorsave Gold 10 Tablet (10)
Consult your doctor before consuming alcohol while taking Atorsave Gold 10 Tablet (10) as it can have severe side effects.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lipitor® (Atorvastatin Calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 637-638
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lipitor® (Atorvastatin Calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 637-638
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lipitor® (Atorvastatin Calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 637-638
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Plavix (clopidogrel bisulfate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 630-631
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 335-336
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Plavix (clopidogrel bisulfate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 630-631
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 335-336
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lipitor® (Atorvastatin Calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 637-638
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lipitor® (Atorvastatin Calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 637-638
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Durlaza (aspirin)
KD Tripathi. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 195-199
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 191-194
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Plavix (clopidogrel bisulfate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 630-631
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 335-336
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lipitor® (Atorvastatin Calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 637-638
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Plavix (clopidogrel bisulfate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 630-631
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 335-336
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Durlaza (aspirin)
KD Tripathi. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 195-199
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 191-194
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lipitor® (Atorvastatin Calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 637-638
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lipitor® (Atorvastatin Calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 637-638
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650